News

Eli Lilly delivered a strong earnings beat with $23B in revenue, driven by surging demand for its GLP-1 drugs Mounjaro (diabetes) and Zepbound (weight loss), which collectively saw volume grow 60% year-on-year. This result reflects the ongoing blockbuster momentum in the obesity and diabetes treatment class, where Lilly competes with Novo Nordisk—a competitive dynamic that's reshaping pharma valuations globally. For Australian investors, this signals sustained strength in the obesity-drug sector and validates the broader healthcare opportunity, though it also highlights Lilly's execution risk if demand eventually normalises.

CVS Health beat Q2 earnings expectations and raised its full-year 2026 guidance, signalling operational resilience in the US healthcare and pharmacy sector. This is positive for the broader healthcare space, though CVS is primarily US-listed and has limited direct ASX exposure. Australian investors with exposure to US healthcare or pharmacy benefit managers via ETFs or direct holdings should note the positive momentum, though the real earnings power and margin sustainability will depend on detailed commentary around PBM margins, which have faced regulatory scrutiny.

Endeavour Group, Australia's second-largest retailer, has written down $311m in assets and reported a significant profit decline, signalling operational stress across its Dan Murphy's and BWS liquor brands and broader retail division. The asset write-down typically reflects management's reassessment of store or asset values amid weaker trading conditions—a red flag for retail fundamentals. For ASX investors, this highlights consumer spending weakness in discretionary categories and raises questions about earnings sustainability, though the 'business reset' commentary suggests management is taking action; watch FY24 guidance and same-store sales trends closely.

Lime has issued forward guidance projecting $1.04B–$1.1B in 2026 revenue with adjusted EBITDA of $265M–$285M, signalling confidence in profitability as the e-scooter company strengthens its balance sheet post-IPO. The outlook suggests the company is trending toward sustainable operations after years of heavy losses, though these are management targets rather than guaranteed results. Australian investors should note micromobility is an emerging but niche sector; the key takeaway is whether Lime can convert scale into real profitability—watch quarterly results and unit economics in coming quarters.

Westgold Resources has announced a major expansion at its Cue Hub, signalling management confidence in the operation's economics and gold market outlook. This capex commitment should support production growth and potentially improve unit costs over the medium term, though execution risk remains. For ASX investors, this demonstrates domestic gold producer resilience and represents a positive signal for the broader materials sector—worth monitoring for FY guidance updates and quarterly production numbers.

Monadelphous Group has secured a significant construction contract from BHP at Nelson's Point, a major project win that should boost the company's revenue pipeline and earnings visibility. For Australian investors, this is material news for MND as it demonstrates strong demand for local engineering services in the resources sector and validates the company's competitive position. Watch for updates on contract size, timeline, and margin expectations in upcoming investor updates, plus any flow-on work from BHP's broader capital program.

Novo Nordisk reported disappointing results for its oral Wegovy (semaglutide) pill, which missed market expectations despite the company upgrading its full-year guidance. The miss is significant because the pill form of the GLP-1 drug is seen as key to mass-market adoption of weight-loss treatments, given it's more convenient than injections. While the improved outlook offers some support, investor concern about Wegovy pill uptake and competition in the obesity drug space is weighing on sentiment—worth monitoring for Australian healthcare investors with pharma exposure through ETFs or direct holdings.

BP's new CEO Meg O'Neill is aggressively reshaping the company's portfolio by divesting non-core assets, including its 60-year-old North Sea operations and the US biogas business Archaea (purchased for $4bn in 2021). This signals a strategic pivot away from the 'green energy' push under predecessor Bernard Looney, refocusing on higher-return capital allocation. For Australian investors, this reflects broader energy sector consolidation and capital discipline among majors—watch for divestment proceeds potentially returning to shareholders or funding higher-yielding oil/gas projects, and monitor whether BP's retreat from renewables influences sector valuations.

Eli Lilly is reporting earnings amid intense investor focus on its obesity and diabetes drug portfolio, particularly Mounjaro and Zepbound, which have driven recent growth. The market will scrutinise revenue guidance, production capacity updates, and competitive positioning as other pharma giants ramp up GLP-1 agonist offerings. For Australian investors, obesity drug adoption trends could influence healthcare spending priorities and ASX pharma valuations, particularly smaller players in the weight-loss space.

Caterpillar reported its strongest earnings beat in five years, driven by surging demand for data-centre construction equipment—a key barometer for AI infrastructure buildout globally. This signals robust capex spending from big tech firms and reflects the breadth of the AI capex cycle beyond just semiconductors. For Australian investors, CAT's strength is relevant as a global industrial bellwether; the ASX-listed CAT also benefits, and the data suggests sustained demand for heavy equipment and construction services supporting the global shift to AI infrastructure.

Apollo Global Management missed Q2 earnings expectations but delivered strong revenue growth driven by its asset management and retirement services divisions. The mixed result—weak bottom line paired with solid top-line performance—suggests operational cost pressures despite growing client assets, which is typical during periods of portfolio transitions or fee compression. Australian investors with exposure to APO or similar global asset managers should monitor whether this signals industry-wide margin pressure or if Apollo-specific execution issues are at play, particularly given the local super and managed funds sector's similar challenges.

Pfizer has announced a $2.5 billion cost-cutting initiative, signalling pressure on its profitability as the company's forward guidance missed analyst expectations. This suggests revenue headwinds—likely from declining COVID-19 vaccine and treatment demand post-pandemic boom—and reflects broader pharma sector challenges around patent cliffs and generic competition. For Australian investors, this matters because Pfizer is a major ASX-listed healthcare holding; the miss could weaken healthcare sector sentiment, though the cost-saving plan may stabilise earnings longer term.

BP's Q2 profit surge to $5.7B—driven by elevated oil and gas prices following supply disruptions—exceeded analyst expectations. While strong earnings support the energy sector near-term, the results highlight how volatile commodity prices inflate profits rather than reflecting operational improvements. Australian investors should note this boosts ASX-listed energy majors like Woodside and Origin, but the 'energy shock' backdrop raises questions about sustainability as global markets stabilise and recession risks loom.

BP reported its strongest profits in four years, driven by elevated oil prices amid geopolitical tensions in Iran. For Australian investors, this matters because higher energy prices typically boost local oil producers like Santos and Woodside, while also pushing up petrol costs and inflation expectations—potentially delaying RBA rate cuts. Watch whether sustained oil prices above $80/barrel trigger another leg of inflation, which could cap ASX200 upside.

American Uranium has upgraded its Indicated mineral resources at the Lo Herma project by 72%, a material expansion that strengthens the project's development case and de-risks future production timelines. This is positive for the company's valuation and reflects better geological understanding or improved extraction economics at the site. For ASX investors, this could support AMU's share price in the near term, though uranium projects remain subject to commodity price cycles and construction/permitting risks—watch for updates on project financing and timeline to production.

Element 25 has secured a long-term binding offtake agreement with Om Holdings, de-risking its manganese production and providing revenue certainty for its planned operations. This is a positive development for the company as offtake agreements are critical for financing and operational planning in the mining sector, particularly for newer producers. Australian investors should monitor E25's execution on project development and broader manganese market dynamics, as tight supply contracts can support pricing but also lock in margins—key will be watching whether this deal supports the company's path to profitability.

Palantir delivered a strong earnings beat with 93% revenue growth and 10% share price surge, driven by both commercial and government segments. The standout performance came from US government contracts (up 90%), which are now the company's largest revenue driver at $809m—a significant concentration risk given ongoing political controversy around immigration enforcement work. For Australian investors, this highlights the growing divergence between US tech valuations: pure-play AI software names are rallying on execution despite reputational headwinds, while the long-term sustainability of government revenue depends on political stability and geopolitical dynamics. Monitor whether this geopolitical risk premia eventually constrains growth or remains priced in.

ON Semiconductor delivered Q2 revenue growth of 9% year-on-year and guided Q3 above consensus expectations, signalling stabilisation in the chip sector after a challenging 2023. This outperformance matters because semiconductors are bellwethers for global tech spending and AI infrastructure demand—strength here suggests supply chains are normalising and equipment cycles may be accelerating. For Australian investors, this is relevant to holdings in tech-exposed funds and ASX semiconductor plays, plus it could underpin broader ASX200 tech momentum, though the sector remains sensitive to US-China trade tensions and cyclical slowdowns.

Microsoft's strong share price momentum—erasing year-to-date losses—reflects market confidence that its massive AI infrastructure investments are beginning to generate returns. This matters because Microsoft is a bellwether for tech sector health and AI adoption; a sustained rally suggests investors believe the company's capital expenditure strategy will translate to revenue growth and margin expansion. Australian investors should watch whether this encourages other mega-cap tech stocks to accelerate capex announcements, and monitor whether MSFT's earnings beat expectations next quarter—key signals that AI investments are converting to actual profit rather than remaining speculative bets.

Boeing has cleared a significant milestone in its recovery from manufacturing and safety setbacks, with the stock rallying and helping to lead the Dow higher. This suggests improving investor confidence in the company's turnaround efforts, though the article lacks specifics on which hurdle was cleared—whether regulatory approval, production targets, or financial metrics. For Australian investors with US equity exposure or holdings in defence-linked stocks, Boeing's recovery is notable given its importance to global industrial sentiment; however, the impact remains sector-specific rather than broad market-moving at this stage.